Abbott (ABT) Rises Higher Than Market: Key Facts

09.04.24 23:50 Uhr

Werte in diesem Artikel
Aktien

94,71 EUR -0,47 EUR -0,49%

Indizes

PKT PKT

16.786,1 PKT -8,8 PKT -0,05%

15.465,6 PKT -88,8 PKT -0,57%

2.528,5 PKT 2,8 PKT 0,11%

5.308,8 PKT 0,6 PKT 0,01%

Abbott (ABT) closed the latest trading day at $112.44, indicating a +1.74% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily gain of 0.15%. On the other hand, the Dow registered a loss of 0.02%, and the technology-centric Nasdaq increased by 0.32%.Shares of the maker of infant formula, medical devices and drugs have depreciated by 8.05% over the course of the past month, underperforming the Medical sector's loss of 4.03% and the S&P 500's gain of 1.65%.The investment community will be closely monitoring the performance of Abbott in its forthcoming earnings report. The company is scheduled to release its earnings on April 17, 2024. The company's earnings per share (EPS) are projected to be $0.96, reflecting a 6.8% decrease from the same quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $9.85 billion, reflecting a 1.02% rise from the equivalent quarter last year.For the full year, the Zacks Consensus Estimates project earnings of $4.62 per share and a revenue of $41.9 billion, demonstrating changes of +4.05% and +4.47%, respectively, from the preceding year.Investors should also take note of any recent adjustments to analyst estimates for Abbott. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Right now, Abbott possesses a Zacks Rank of #3 (Hold).From a valuation perspective, Abbott is currently exchanging hands at a Forward P/E ratio of 23.94. This valuation marks a premium compared to its industry's average Forward P/E of 21.64.One should further note that ABT currently holds a PEG ratio of 2.66. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The average PEG ratio for the Medical - Products industry stood at 2.37 at the close of the market yesterday.The Medical - Products industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 96, positioning it in the top 39% of all 250+ industries.The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.Free – 5 Dividend Stocks to Fund Your Retirement Zacks Investment Research has released a Special Report to help you prepare for retirement with 5 diverse stocks that pay whopping dividends. They cut across property management, upscale outlets, financial institutions, and a couple of strong energy producers.5 Dividend Stocks to Include in Your Retirement Strategy is packed with unconventional wisdom and insights you won’t get from your neighborhood financial planner.Download Now – Today It’s FREE >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf Abbott Laboratories

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Abbott Laboratories

NameHebelKOEmittent
NameHebelKOEmittent
Werbung

Quelle: Zacks

Nachrichten zu Abbott Laboratories

Analysen zu Abbott Laboratories

DatumRatingAnalyst
27.08.2020Abbott Laboratories SellGoldman Sachs Group Inc.
16.10.2018Abbott Laboratories OverweightBarclays Capital
25.01.2018Abbott Laboratories BuyStifel, Nicolaus & Co., Inc.
15.12.2017Abbott Laboratories OutperformBMO Capital Markets
19.10.2017Abbott Laboratories BuyStifel, Nicolaus & Co., Inc.
DatumRatingAnalyst
16.10.2018Abbott Laboratories OverweightBarclays Capital
25.01.2018Abbott Laboratories BuyStifel, Nicolaus & Co., Inc.
15.12.2017Abbott Laboratories OutperformBMO Capital Markets
19.10.2017Abbott Laboratories BuyStifel, Nicolaus & Co., Inc.
19.10.2017Abbott Laboratories OutperformRBC Capital Markets
DatumRatingAnalyst
23.07.2015Abbott Laboratories Equal WeightBarclays Capital
27.03.2015Abbott Laboratories Equal WeightBarclays Capital
30.01.2015Abbott Laboratories Equal WeightBarclays Capital
07.01.2013Abbott Laboratories haltenDeutsche Bank Securities
29.11.2012Abbott Laboratories neutralSarasin Research
DatumRatingAnalyst
27.08.2020Abbott Laboratories SellGoldman Sachs Group Inc.
25.10.2011Abbott Laboratories sellCitigroup Corp.
05.10.2011Abbott Laboratories sellCitigroup Corp.
22.11.2006Advanced Medical Optics sellCitigroup
11.09.2006Abbott Laboratories reduceUBS

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Abbott Laboratories nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"